Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …